The India biosimilar market size was valued at INR 4.37 Billion in 2024, driven by the rising prevalence of chronic diseases across the region. The market is expected to grow at a CAGR of 14.20% during the forecast period of 2025-2034, with the values likely to rise from INR 16.49 Billion by 2034.
Base Year
Historical Period
Forecast Period
Value in INR Billion
2025-2034
India Biosimilar Market Outlook
*this image is indicative*
A biosimilar is a biologic medical product that is almost identical to an original product launched by a different company. They are also known as subsequent entry biologics (SEBs) or follow-on biologics. These are the approved versions of innovator products and can be manufactured when the patent of the original product expires. Biosimilars can make several expensive and critical treatments more accessible to more people as they may be more affordable or be available in bulk quantities.
With the rising incidence of chronic diseases, the India biosimilar market demand has grown. As a result, there have been several significant initiatives from the private and state-owned organizations to mitigate the rising burden of morbidities.
The region is gaining significant pharmaceutical attention to meet the high demand and it is heavily impacted by the rising investments to build the medical infrastructure and offer rapid, accurate and affordable outcomes to the patients. Dr. Reddy’s Laboratories, a prominent pharmaceutical player in the region, has identified the biosimilar segment as a key priority area. This indicates the ongoing trend of rising emphasis on the area.
To push the production and application of biosimilars, the government has also eased out on stringent regulations and encouraging tie-ups between foreign and indigenous companies. In July 2023, India’s Biocon Biologics launched a biosimilar version of AbbVie’s rheumatoid arthritis drug Humira in the United States.
Biocon Biologics has also received the marketing authorization for Yesafili, an ophthalmology product which is a biosimilar to the reference product Eylea (Aflibercept) from the UK's Medicines and Healthcare products Regulatory Agency (MHRA). As a result, the India biosimilar market share is expected to have a significant global impact in coming years as well.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
India Biosimilar Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Class
Market Breakup by Manufacturing Type
Market Breakup by Applications
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The growing demand for biosimilars due to their cost-effectiveness has been aiding the industry growth. The market is finding further impetus for its growth in the several cost-saving initiatives undertaken by governments as well as third-party payers, which, as a result, are encouraging the use of biosimilars as opposed to branded biologics, thereby propelling the demand for biosimilars.
Acknowledging the need for pharma innovation in the country, the pharmaceutical department proposed a PRIP (Promotion of Research and Innovation in Pharma MedTech Sector) scheme in August 2023. This scheme outlays a budget of INR 5000 crores and is entirely focused on strengthening the research infrastructure in the country. Such initiatives are further projected to add to the India biosimilars market value.
However, some factors, such as negative perception from physicians, lower price differential as compared to small-molecule generics, patent extensions, and others, are hampering the growth of the market in India.
India overtaking China to become the most populous country in the world has also accelerated the India biosimilars market growth further. The growing geriatric population within the region has become an area of concern for the government. The patents of numerous biologic drugs have expired, and some of the blockbuster drugs are further expected to have their patent protection expire in the upcoming years, thus, offering tremendous market opportunities for biosimilar manufacturers in India in the forecast period.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about INR 4.37 Billion in 2024, driven by rising activities and strategic partnerships and the evolving regulatory landscape.
The market is anticipated to grow at a CAGR of 14.20% during the forecast period of 2025-2034, likely to reach a market value of INR 16.49 Billion by 2034.
The market demand has increased with the high prevalence of chronic diseases in the continuously rising geriatric population, along with a rise in research and development and overall expansion of the healthcare sector.
The current market trend revolves around the emergence of new biosimilars in the market. For instance, in July 2023, India’s Biocon Biologics launched a biosimilar version of AbbVie’s rheumatoid arthritis drug Humira.
The major applications include blood disorders, growth hormonal deficiency, chronic and autoimmune disorders, oncology, and other applications.
Product class includes monoclonal antibodies, recombinant hormones, immunomodulators, and anti-inflammatory agents, among other product classes.
The significant manufacturing types include in-house manufacturing and contract manufacturing.
Key players involved in the market are Pfizer Inc., Eli Lilly and Company, Celltrion Healthcare, Viatris Inc. (Mylan), Novartis AG, Samsung Bioepis Co. Ltd., Stada Arzneimittel AG, Teva Pharmaceutical Industries Ltd., Intas Pharmaceutical Ltd., LG Life Sciences Inc., Biocon Limited, Amgen Inc., Dr. Reddy's Laboratories, Coherus Biosciences Inc. and Biocad.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Class |
|
| Breakup by Manufacturing Type |
|
| Breakup by Applications |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share